Overview of ECHELON-1 Study for Hodgkin Lymphoma

Updates from the ECHELON-1 Trial Utilizing Brentuximab in Hodgkin’s LymphomaПодробнее

An updated analysis of ECHELON-1: 1L brentuximab vedotin + chemotherapy in stage III/IV classical HLПодробнее

Hodgkin Lymphoma: ECHELON-1 Update from ASCO 2022Подробнее

Five year update of ECHELON-1 for classical Hodgkin lymphomaПодробнее

Results of ECHELON-1 study for Hodgkin LymphomaПодробнее

What a New Hodgkin Lymphoma Treatment Means to Frontline PractitionersПодробнее

A 10-year PFS simulation model based on the ECHELON-1 trial in Hodgkin lymphomaПодробнее

Moving Beyond One Size Fits All for Angioimmunoblastic T-Cell LymphomaПодробнее

Phase III ECHELON-1 study: Updated results of brentuximab vedotin + chemotherapy for untreated cHLПодробнее

ECHELON-1 Trial Shows Continued Efficacy Over Time in Hodgkin LymphomaПодробнее

Andrea Gallamini, EHA 2019 – Three-year Update of the ECHELON-1 StudyПодробнее

Updates from the ECHELON-1 studyПодробнее

Updated ECHELON-1 Findings Demonstrate Potential Toxicities of Brentuximab Vedotin Combo in cHLПодробнее

5-Year Update of the ECHELON-1 StudyПодробнее

Dr. Kaplan on the Phase III ECHELON-1 Trial in Hodgkin LymphomaПодробнее

Research Builds On Positive ECHELON-1 Study in Hodgkin LymphomaПодробнее

5-Year Update of the ECHELON-1 StudyПодробнее

Dr. Straus on the 3-Year Results of the ECHELON-1 Study in Hodgkin LymphomaПодробнее

Brentuximab Vedotin and Chemotherapy in Classical HLПодробнее